Background and Aims: Attempts at achieving cytokine homeostasis include blood purification to deliver cytokine removal. Assessment of ex vivo studies for optimal operating conditions is a vital step. Methods: We conducted a systematic search for ex vivo studies on cytokine removal using known modalities of extracorporeal circulation. We selected 29 articles and analyzed data according to clearance, sieving coefficient, ultrafiltrate concentration and percentage removal. Results: We identified four main techniques for cytokine removal: standard techniques, high cut-off (HCO) techniques, adsorption techniques and combined plasma filtration adsorption. HCO hemofiltration (HCO/HF) showed greatest consistency in cytokine removal among all approaches. Mean albumin clearance with HCO filters was 3.74 ml/min. Conclusion: Ex vivo data support the view that HCO/HF is the most consistently effective approach in terms of sieving and clearance. Further investigation of HCO/HF in randomized controlled trials in animal models and humans seems desirable.

Keywords:
Cytokines, Hemofiltration, Plasmapheresis, Plasma exchange, High cut-off filters, Couples plasma filtration adsorption, Continuous renal replacement therapy
1.
Adib-Conquy M, Cavaillon JM: Stress molecules in sepsis and systemic inflammatory response syndrome. FEBS Lett 2007;581:3723–3733.
2.
Rubartelli A, Lotze MT: Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol 2007;28:429–436.
3.
Bone RC: Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 1996;24:1125–1128
4.
Kellum JA, Bellomo R, Mehta R, Ronco C: Blood purification in non-renal critical illness. Blood Purif 2003;21:6–13.
5.
Fisher CJ Jr, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, et al: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994;271:1836–1843.
6.
Opal SM, Fisher CJ Jr, Dhainaut JF, Vincent JL, Brase R, Lowry SF, et al: Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 1997;25:1115–1124.
7.
Hansen TG, Tønnesen E, Toft P, Bendtzen K: Interleukin-6 (IL-6) is not removed from plasma during experimental haemofiltration. Acta Anaesthesiol Scand 1998;42:1129.
8.
Skogby M, Adrian K, Friberg LG, Mellgren G, Mellgren K: Influence of hemofiltration on plasma cytokine levels and platelet activation during extra corporeal membrane oxygenation. Scand Cardiovasc J 2000;34:315–320.
9.
Schindler R: Elimination of cytokines from plasma by ultrafiltration using conventional polysulfone or DIAPES membranes. Contrib Nephrol. Karger, Basel, 2003, vol138, pp 37–42.
10.
Haase M, Bellomo R, Morger S, Baldwin I, Boyce N: High cut-off point membranes in septic acute renal failure: a systematic review. Int J Artif Organs 2007;30:1031–1041.
11.
Tetta C, Cavaillon JM, Schulze M, Ronco C, Ghezzi PM, Camussi G, Serra AM, Curti F, Lonnemann G: Removal of cytokines and activated complement components in an experimental model of continuous plasma filtration coupled with sorbent adsorption. Nephrol Dial Transplant 1998;13:1458–1464.
12.
Cole L, Bellomo R, Davenport P, Tipping P, Uchino S, Tetta C, Ronco C: The effect of coupled haemofiltration and adsorption on inflammatory cytokines in an ex vivo model. Nephrol Dial Transplant 2002;17:1950–1956.
13.
Bordoni V, Bolgan I, Brendolan A, Crepaldi C, Gastaldon F, D’intini V, et al: Caspase-3 and -8 activation and cytokine removal with a novel cellulose triacetate super-permeable membrane in an in vitro sepsis model. Int J Artif Organs 2003;26:897–905.
14.
Steczko J, Ash SR, Blake DE, Carr DJ, Bosley RH: Cytokines and endotoxin removal by sorbents and its application in push-pull sorbent-based pheresis: the BioLogic-DTPF system. Artif Organs 1999;23:310–318.
15.
Mariano F, Fonsato V, Lanfranco G, Pohlmeier R, Ronco C, Triolo G, et al: Tailoring high-cut-off membranes and feasible application in sepsis-associated acute renal failure: in vitro studies. Nephrol Dial Transplant 2005;20:1116–1126.
16.
Lee WC, Uchino S, Fealy N, Baldwin I, Panagiotopoulos S, Goehl H, et al: Super high flux hemodialysis at high dialysate flows: an ex vivo assessment. Int J Artif Organs 2004;27:24–28.
17.
Morgera S, Klonower D, Rocktäschel J, Haase M, Priem F, Ziemer S, et al: TNF-alpha elimination with high cut-off haemofilters: a feasible clinical modality for septic patients? Nephrol Dial Transplant 2003;18:1361–1369.
18.
Uchino S, Bellomo R, Morimatsu H, Goldsmith D, Davenport P, Cole L, et al: Cytokine dialysis: an ex vivo study. ASAIO J 2002;48:650–653.
19.
Uchino S, Bellomo R, Goldsmith D, Davenport P, Cole L, Baldwin I, et al: Super high flux hemofiltration: a new technique for cytokine removal. Intensive Care Med 2002;28:651–655.
20.
Uchino S, Bellomo R, Goldsmith D, Davenport P, Cole L, Baldwin I, et al: Cytokine removal with a large pore cellulose triacetate filter: an ex vivo study. Int J Artif Organs 2002;25:27–32.
21.
Cole L, Bellomo R, Davenport P, Tipping P, Ronco C: Cytokine removal during continuous renal replacement therapy: an ex vivo comparison of convection and diffusion. Int J Artif Organs 2004;27:388–397.
22.
Teraoka S, Mineshima M, Hoshino T, Ishimori I, Kaneko I, Sato Y, et al: Can cytokines be removed by hemofiltration or hemoadsorption? ASAIO J 2000;46:448–451.
23.
Bouman CS, van Olden RW, Stoutenbeek CP: Cytokine filtration and adsorption during pre- and postdilution hemofiltration in four different membranes. Blood Purif 1998;16:261–268.
24.
Glogowski KR, Stammers AH, Niimi KS, Tremain KD, Muhle ML, Trowbridge CC: The effect of priming techniques of ultrafiltrators on blood rheology: an in vitro evaluation. Perfusion 2001;16:221–228.
25.
Skogby M, Adrian K, Friberg LG, Mellgren G, Mellgren K: Influence of hemofiltration on plasma cytokine levels and platelet activation during extra corporeal membrane oxygenation. Scand Cardiovasc J 2000;34:315–320.
26.
Nagaki M, Hughes RD, Lau JY, Williams R: Removal of endotoxin and cytokines by adsorbents and the effect of plasma protein binding. Int J Artif Organs 1991;14:43–50.
27.
Weber V, Hartmann J, Linsberger I, Falkenhagen D: Efficient adsorption of tumor necrosis factor with an in vitro set-up of the microspheres-based detoxification system. Blood Purif 2007;25:169–174.
28.
Goldfarb S, Golper TA: Proinflammatory cytokines and hemofiltration membranes. J Am Soc Nephrol 1994;5:228–232.
29.
Sandeman SR, Howell CA, Mikhalovsky SV, Phillips GJ, Lloyd AW, Davies JG, et al: Inflammatory cytokine removal by an activated carbon device in a flowing system. Biomaterials 2008;29:1638–1644.
30.
Oda S, Hirasawa H, Shiga H, Nakanishi K, Matsuda K, Nakamura M, et al: Cytokine adsorptive property of various adsorbents in immunoadsorption columns and a newly developed adsorbent: an in vitro study. Blood Purif 2004;22:530–536.
31.
Song M, Winchester J, Albright RL, Capponi VJ, Choquette MD, Kellum JA: Cytokine removal with a novel adsorbent polymer. Blood Purif 2004;22:428–434.
32.
Zimmermann M, Busch K, Kuhn S, Zeppezauer M: Endotoxin adsorbent based on immobilized human serum albumin. Clin Chem Lab Med 1999;37:373–379 .
33.
van Bommel EF, Hesse CJ, Jutte NH, Zietse R, Bruining HA, Weimar W: Cytokine kinetics (TNF-α, IL-1β, IL-6) during continuous hemofiltration: a laboratory and clinical study. Contrib Nephrol. Karger, Basel, 1995, vol 116, pp 62–75.
34.
Nagaki M, Hughes RD, Keane HM, Lau JY, Williams R: In vitro plasma perfusion through adsorbents and plasma ultrafiltration to remove endotoxin and cytokines. Circ Shock 1992;38:182–188.
35.
Taniguchi T, Hirai F, Takemoto Y, Tsuda K, Yamamoto K, Inaba H, Sakurai H, Furuyoshi S, Tani N: A novel adsorbent of circulating bacterial toxins and cytokines: the effect of direct hemoperfusion with CTR column for the treatment of experimental endotoxemia. Crit Care Med 2006;34:800–806.
36.
Awad SS, Sawada S, Soldes OS, Rich PB, Klein R, Alarcon WH, et al: Can the clearance of tumor necrosis factor alpha and interleukin 6 be enhanced using an albumin dialysate hemodiafiltration system? ASAIO J 1999;45:47–49.
37.
Kellum JA, Song M, Venkataraman R: Hemoadsorption removes tumor necrosis factor, interleukin-6, and interleukin-10, reduces nuclear factor-ĸB DNA binding, and improves short-term survival in lethal endotoxemia. Crit Care Med 2004;32:801–805.
38.
Schefold JC, Hasper D, Jörres A: Organ crosstalk in critically ill patients: hemofiltration and immunomodulation in sepsis. Blood Purif 2009;28:116–123.
39.
Lever A, Mackenzie I: Sepsis: definition, epidemiology, and diagnosis. BMJ 2007;335:879–832.
40.
Schetz M, Ferdinande P, Van den Berghe G, Verwaest C, Lauwers P: Removal of pro-inflammatory cytokines with renal replacement therapy: sense or nonsense? Intensive Care Med 1995;21:169–176.
41.
Morgera S, Slowinski T, Melzer C, Sobottke V, Vargas-Hein O, Volk T, et al: Renal replacement therapy with high-cutoff hemofilters: impact of convection and diffusion on cytokine clearances and protein status. Am J Kidney Dis 2004;43:444–453.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.